Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($1.36), $0.01 better than the analyst estimate of ($1.37). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $3.6 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.